Revolution gets selective
The group’s latest update focused on new data with the KRAS G12C inhibitor elironrasib.
The month ahead: May’s remaining events
Conference activity picks up, with the big one – ASCO – at the end of the month.
Unharmonious ivonescimab reveal for Summit
The same trial that sent Summit up 272% sees the stock crash 36%.
AACR 2025 – Revolution shows lung promise
But half the responses with the KRAS G12D inhibitor zoldonrasib are unconfirmed.
AACR 2025 – Boehringer still has broad zongertinib hopes
Data in HER2-mutated NSCLC still look good, and studies in HER2-amplified tumours continue.
Ivo combo beats Tevimbra, but can it beat Keytruda?
The PD-1 x VEGF molecule's latest win comes from Akeso's Harmoni-6 trial.
